Q-omics provides the consensus-scored GSDMA profile across patient tissues and cancer cell-line models. GSDMA expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GSDMA is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, GSDMA protein abundance shows 13,181 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SCLC, COAD, and HNSC as cancer lineages where GSDMA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSDMA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSDMA survival associations across molecular data types. GSDMA RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSDMA RNA expression–survival associations across cancer types. High GSDMA expression shows unfavorable associations in ACC and STAD, but favorable associations in SCLC, KIRC, SKCM and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for GSDMA RNA expression.
This table summarizes GSDMA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GSDMA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSDMA shows higher tumor expression in COAD, THCA, KIRC, LUAD, READ and LUSC. The COAD box plot shows higher GSDMA RNA expression in tumor versus normal tissue (log2 FC = +2.880, t-test p < 0.001).
This table shows molecular features associated with GSDMA in patient tissues and cancer cell lines. In patient samples, GSDMA shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSDMA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
